Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 3, 2008, Pages 295-299

  Hovde, Laurie B ^a   Simonson, Dana A ^a   Rotschafer, John C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

DNA gyrase; Levofloxacin; Moxifloxacin; Streptococcus pneumoniae; Topoisomerase IV

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; DNA TOPOISOMERASES; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; MUTATION, MISSENSE; OFLOXACIN; POLYMERASE CHAIN REACTION; QUINOLINES; SEQUENCE ANALYSIS, DNA; STREPTOCOCCUS PNEUMONIAE;

EID: 39149132111     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.10.007     Document Type: Article

References (15)

1. Canton R., Morosini M., Enright M.C., and Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the PROTEKT surveillance programme. J. Antimicrob. Chemother. 52 (2003) 944-952
2. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-fifth edition. NCCLS Document M7-A5 (2000), CLSI, Wayne (PA)
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. M100-S15 (2005), CLSI, Wayne (PA)
4. Davies T.A., Yee Y.C., Goldschmidt R., Bush K., Sahm D.F., and Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J. Antimicrob. Chemother. 57 (2006) 437-442
5. Jorgensen J.H., Weigel L.M., Ferraro M.J., Swenson J.M., and Tenover F.C. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43 (1999) 329-334
6. Kawamura-Sato K., Hasegawa T., Torii K., Ito H., and Ohta M. Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. Curr. Microbiol. 51 (2005) 27-30
7. Li X., Zhao X., and Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46 (2002) 522-524
8. Munoz R., Bustamante M., and de la Campa A.G. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J. Bacteriol. 177 (1995) 4166-4170
9. Notredame C., Higgins D., and Heringa J. T-Coffee: a novel method for multiple sequence alignments. J. Mol. Biol. 302 (2000) 205-217
10. Pan X.S., and Fisher L.M. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178 (1996) 4060-4069
11. Pan X.S., and Fisher L.M. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42 (1998) 2810-2816
12. Pan X.S., and Fisher L.M. Streptococcus pneumoniae DNA gyrase and topoisomerase: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43 (1999) 1129-1136
13. Pestova E., Millichap J., Noskin G., and Peterson L. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45 (2000) 583-590
14. Sanders C.A., Nieda R.R., and Desmond E.P. Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J. Clin. Microbiol. 42 (2004) 5225-5228
15. Wickman P.A., Hossain A., Thomson K.S., and Hanson N.D. Moxifloxacin has reduced potential to select mutational fluoroquinolone resistance in Streptococcus pneumoniae. Abstracts of the 102nd General Meeting of the American Society for Microbiology, Park City, Utah, A-17 (2002)